Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia.
Future Microbiol
; 14: 927-939, 2019 07.
Article
en En
| MEDLINE
| ID: mdl-31333062
Despite the increasing availability of antibiotics with activity against pathogens that cause community-acquired pneumonia (CAP), CAP remains a major cause of morbidity, hospital admissions and re-admissions, and mortality. Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against both typical and atypical CAP pathogens. In this review of the medical literature, we summarize the available information, including mounting clinical evidence, about lefamulin and its potential value in CAP.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neumonía
/
Compuestos Policíclicos
/
Tioglicolatos
/
Bacterias
/
Diterpenos
/
Antibacterianos
Límite:
Humans
Idioma:
En
Revista:
Future Microbiol
Asunto de la revista:
MICROBIOLOGIA
Año:
2019
Tipo del documento:
Article
Pais de publicación:
Reino Unido